Lyrica Will Be Available In Fall, Pfizer Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer announces approval of the third indication for Lyrica (pregabalin) on the same day that comments are due on the Drug Enforcement Agency’s proposed scheduling for the product. The Neurontin follow-on will launch with three out of four original indications.
You may also be interested in...
Pfizer Launches Lyrica Nine Months After First Approval
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
Pfizer Launches Lyrica Nine Months After First Approval
Pregabalin gestational period encompassed approval of three indications, DEA scheduling and production of packaging.
Lyrica Controlled Substance Scheduling Finalized By DEA
Pfizer’s pregabalin will launch in the fall for three indications as a Schedule V controlled substance.